AOD9604: Discovery and Regulatory History

Introduction

AOD9604 is a synthetic hexadecapeptide derived from the C-terminal region of human growth hormone (hGH). Its research history spans approximately three decades — from foundational biochemical studies in Australian university laboratories in the early 1990s, through one of the more thoroughly executed Phase II clinical development programs for a synthetic hGH fragment, and into a subsequent regulatory transition to a Generally Recognized as Safe (GRAS) dietary ingredient determination in the United States. The AOD9604 program generated a durable body of peer-reviewed literature, established an extensive human safety dataset across six controlled trials, and produced mechanistic data on hGH C-terminal fragments that continues to inform lipid pharmacology research.

Discovery Period

The scientific lineage of AOD9604 begins with the broader question of whether the diverse pharmacological actions of full-length hGH could be attributed to discrete structural domains of the molecule. Human growth hormone had long been known to exert both lipolytic and antilipogenic effects on adipose tissue, but these metabolic properties were accompanied by systemic effects — including insulin resistance and stimulation of IGF-1 production — that limited the hormone's utility as a research tool for studying lipid metabolism in isolation. The development of synthetic peptides to probe discrete GH-axis pathways parallels the contemporaneous research lineage of GH secretagogues such as CJC-1295 with DAC, which pursued a complementary strategy of prolonging endogenous GH release rather than isolating a C-terminal domain fragment.

F.M. Ng and colleagues at Monash University in Melbourne, Australia, pursued this question through systematic study of synthetic C-terminal hGH peptides during the early 1990s. A 1993 paper by Wu and Ng established that a synthetic peptide corresponding to residues 177–191 of hGH reproduced the antilipogenic activity of the intact molecule in isolated rat adipose tissue, with activity comparable in magnitude to that of full-length hGH [1]. Critically, the fragment also appeared to operate independently of the GH receptor signaling axis — a pharmacological property that distinguished it from full-length hGH and made it a more selective research tool for studying lipid regulatory pathways.

A follow-up in vivo study published in 1994 by Natera, Jiang, and Ng reported that chronic treatment of genetically obese C57BL/6J (ob/ob) mice with synthetic hGH 177–191 was associated with reduced cumulative body weight gain and reduced adipose tissue mass compared to control animals, with concomitant inhibition of lipogenesis in adipose tissue [2]. These findings provided the initial preclinical in vivo evidence for metabolically relevant activity of the C-terminal hGH fragment and laid the foundation for the compound development program that followed.

Early Research and Compound Development (1994–2001)

Following the initial characterization of hGH 177–191, Metabolic Pharmaceuticals Pty Ltd, an Australian biotechnology company, licensed the intellectual property from Monash University and began systematic development of a stabilized analogue. The company introduced an N-terminal tyrosine residue to the 177–191 sequence, producing Tyr-hGH177–191 — the molecule designated AOD9604. This structural modification was introduced to confer greater in vivo stability relative to the unmodified fragment. An intermediate compound, AOD9401, was also studied during this developmental period and contributed substantially to the mechanistic literature.

A 2000 study by Heffernan, Jiang, Thorburn, and Ng published in the American Journal of Physiology reported that oral administration of AOD9401 in ob/ob mice was associated with reduced body weight gain, reduced adipose lipogenic activity, increased lipolytic activity and fat oxidation, and acute increases in energy expenditure — providing evidence for oral bioavailability of a GH C-terminal fragment in a rodent model and strengthening the case for an oral pharmaceutical development path [3].

A companion 2000 publication in the Journal of Molecular Endocrinology examined AOD9401 in Zucker fatty rats, reporting enzyme-level effects on hormone-sensitive lipase and acetyl-CoA carboxylase in isolated adipose tissue consistent with both lipolytic and antilipogenic mechanisms [4]. Together, the two 2000 publications established a coherent biochemical model of how the C-terminal hGH fragment acted on adipose lipid metabolism.

A pivotal 2001 study by Heffernan et al. published in Endocrinology examined AOD9604 specifically in obese mice and β3-adrenergic receptor knock-out animals, characterizing the compound's relationship to β3-AR signaling and providing evidence that β3-AR-dependent pathways contribute to its lipolytic activity over the course of chronic treatment [5]. In the same year, Heffernan et al. published in the International Journal of Obesity reporting that a modified C-terminal hGH fragment produced fat oxidation and body-weight-related changes in obese mice without inducing hyperglycemia or reducing insulin secretion — a metabolic differentiation from full-length hGH considered favorable for the developing compound's profile [6].

Pharmaceutical Development and Clinical Trials (2001–2007)

Building on the accumulated preclinical evidence base, Metabolic Pharmaceuticals advanced AOD9604 into human clinical investigation. Six randomized, double-blind, placebo-controlled trials were conducted, encompassing two intravenous pilot studies, two oral dosing pilot studies, and two oral Phase IIb efficacy and safety studies [7]. This clinical program represented one of the largest controlled investigations of a synthetic hGH C-terminal fragment in human participants.

The safety findings across all six trials were reported by Stier, Vos, and Kenley (2013) as uniformly favorable. AOD9604 displayed a tolerability profile indistinguishable from placebo, with no statistically significant effects detected on serum IGF-1, fasting glucose, insulin, HbA1c, cortisol, or thyroid hormones at any dose tested, and no serious adverse events attributed to the compound across the clinical program [7]. These findings confirmed the preclinical prediction that the C-terminal fragment would not carry the IGF-1 and insulin-resistance liabilities of full-length hGH.

The Phase IIb program culminated in the OPTIONS study — a 24-week multicenter randomized controlled trial enrolling 536 obese adults across multiple oral doses. The study completed enrollment ahead of schedule and concluded in late 2006. While the lowest-dose arm demonstrated numerically greater weight change compared to placebo at 12 weeks, the pre-specified primary endpoint for statistically significant weight reduction across the full dose range and 24-week timeframe was not met [7]. The OPTIONS study did not identify a safety concern; the lack of a statistically significant efficacy signal across the dose range studied informed the subsequent decision about the pharmaceutical development path.

Regulatory Milestones

2007: Conclusion of pharmaceutical development program. Following the OPTIONS study outcome, Metabolic Pharmaceuticals concluded the program seeking approval of AOD9604 as a prescription obesity treatment. The decision was based on the primary endpoint result; the compound's safety profile remained intact.

GRAS determination (US FDA). The extensive clinical and nonclinical safety dataset generated during the development program was subsequently submitted in support of a Generally Recognized as Safe determination for AOD9604 as a dietary ingredient for use in foods, beverages, and dietary supplements, conditional on publication of the pre-existing safety data [7,8]. Moré and Kenley (2014) published the consolidated nonclinical safety dataset in the Journal of Endocrinology and Metabolism, fulfilling the publication condition associated with the GRAS determination [8]. The nonclinical program reported in that publication encompassed chronic rat and monkey toxicology studies, pharmacokinetic characterization, and genotoxicity assessments — all yielding favorable findings [8].

The GRAS designation establishes that AOD9604 is considered safe for the described food-ingredient use. It is not equivalent to drug approval for any therapeutic indication and does not constitute a finding of efficacy. The synthesis methods, purity standards, and third-party verification practices applied to research-grade material are described in the AOD9604 sourcing and quality article. Research-grade AOD9604 from SpartaLabs is manufactured under cGMP-aligned processes with full chain-of-custody documentation for each batch.

2015: Musculoskeletal research. A 2015 study by Kwon, Park, and Lee examined intra-articular AOD9604 administration in a rabbit osteoarthritis model and reported cartilage-related findings in the combined AOD9604 and hyaluronic acid group [9]. This study extended the AOD9604 literature into musculoskeletal biology, an area distinct from the metabolic indications that had characterized the pharmaceutical development program. It represents the most recent primary research contribution identified in the peer-reviewed AOD9604 literature.

Current Research Landscape

As of the peer-reviewed literature available through mid-2026, AOD9604 has not progressed into additional human clinical trials following the 2007 conclusion of the Metabolic Pharmaceuticals program. The compound's GRAS status in the United States has created a pathway for its inclusion in food and supplement products, distinct from the prescription drug context in which it was originally developed.

The primary body of peer-reviewed literature on AOD9604 was produced between 1993 and 2015. AOD9604 remains a reference compound in studies examining the dissociation of hGH's lipolytic and growth-promoting pharmacological activities, and the questions identified during the development program — including primary receptor identification, the mechanism of oral bioavailability, and the translational pharmacology of hGH C-terminal fragments — remain active areas within the broader peptide and endocrinology research literature. Research interest in growth hormone fragment pharmacology more broadly continues, and the mechanistic groundwork laid by the Monash University and Metabolic Pharmaceuticals programs provides a published foundation for future investigators in this area.

References

1. Wu Z, Ng FM. Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone. Biochemistry and Molecular Biology International. 1993;30(1):187–196. PMID: 8358331.

2. Natera SH, Jiang WJ, Ng FM. Reduction of cumulative body weight gain and adipose tissue mass in obese mice: response to chronic treatment with synthetic hGH 177-191 peptide. Biochemistry and Molecular Biology International. 1994;33(5):1011–1021. PMID: 7987248.

3. Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. American Journal of Physiology – Endocrinology and Metabolism. 2000;279(3):E501–E507. https://doi.org/10.1152/ajpendo.2000.279.3.E501

4. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Molecular and cellular actions of a structural domain of human growth hormone (AOD9401) on lipid metabolism in Zucker fatty rats. Journal of Molecular Endocrinology. 2000;25(3):287–298. PMID: 11116208.

5. Heffernan MA, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knock-out mice. Endocrinology. 2001;142(12):5182–5189. https://doi.org/10.1210/endo.142.12.8522

6. Heffernan M, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. International Journal of Obesity. 2001;25(10):1442–1449. PMID: 11673763.

7. Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. Journal of Endocrinology and Metabolism. 2013;3(1–2):7–15. https://www.jofem.org/index.php/jofem/article/view/157

8. Moré MI, Kenley D. Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic health. Journal of Endocrinology and Metabolism. 2014;4(3):116–126. https://jofem.org/index.php/jofem/article/view/213

9. Kwon DR, Park GY, Lee SC. Effect of intra-articular injection of AOD9604 with or without hyaluronic acid in rabbit osteoarthritis model. Annals of Clinical and Laboratory Science. 2015;45(4):426–432. PMID: 26275694.